Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).Audreylie Lemelin, Daniel Yick Chin Heng, Bradley A. McGregor et al.|Journal of Clinical Oncology|2023Cited by 0
Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records dataEvan C. Chen, Gabriela Hobbs, Xiaoqin Yang et al.|Blood|2025Cited by 0